Seres grabs $20M on PhI­II mi­cro­bio­me launch; Gilead sub­mits NDA; Alk­er­mes be­gins Phase II­Ib study

→  Seres $MCRB is tak­ing an­oth­er step for­ward in its come­back ef­fort on a mi­cro­bio­me drug that rat­tled every­one in the field when it failed a mid-stage study. The biotech says that it has learned from its set­back and has now start­ed a study for pa­tients with mul­ti­ple re­cur­rent C. dif­fi­cile in­fec­tion that it’s hop­ing will serve as the piv­otal Phase III for SER-109. That move — the most ad­vanced mi­cro­bio­me study in the gut re­search world — was worth a $20 mil­lion mile­stone pay­ment from its part­ners at Nestlé Health Sci­ence.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.